ES2191260T3 - Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. - Google Patents

Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos.

Info

Publication number
ES2191260T3
ES2191260T3 ES98310580T ES98310580T ES2191260T3 ES 2191260 T3 ES2191260 T3 ES 2191260T3 ES 98310580 T ES98310580 T ES 98310580T ES 98310580 T ES98310580 T ES 98310580T ES 2191260 T3 ES2191260 T3 ES 2191260T3
Authority
ES
Spain
Prior art keywords
imidazolidin
ona
derivatives
useful
target agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98310580T
Other languages
English (en)
Inventor
Joseph Peter Lyssikatos
Bingwei Vera Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2191260T3 publication Critical patent/ES2191260T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS REPRESENTADOS POR LA FORMULA 1: Y A SALES FARMACEUTICAMENTE ACEPTABLES Y A SOLVATOS DE LOS MISMOS, DONDE Z, R, R 3 Y R 4 REPRESENTAN LO QUE SE DEFINE EN LA DESCRIPCION. LA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS DE FORMULA 1 Y A PROCEDIMIENTOS DE INHIBICION DEL CRECIMIENTO CELULAR ANORMAL, INCLUYENDO CANCERES, EN UN MAMIFERO, MEDIANTE LA ADMINISTRACION DE DICHOS COMPUESTOS A DICHO MAMIFERO.
ES98310580T 1997-12-30 1998-12-22 Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. Expired - Lifetime ES2191260T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7001097P 1997-12-30 1997-12-30

Publications (1)

Publication Number Publication Date
ES2191260T3 true ES2191260T3 (es) 2003-09-01

Family

ID=22092561

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98310580T Expired - Lifetime ES2191260T3 (es) 1997-12-30 1998-12-22 Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos.

Country Status (10)

Country Link
US (1) US6080769A (es)
EP (1) EP0928788B1 (es)
JP (1) JPH11236333A (es)
AT (1) ATE232520T1 (es)
BR (1) BR9805734A (es)
CA (1) CA2257016C (es)
DE (1) DE69811329T2 (es)
DK (1) DK0928788T3 (es)
ES (1) ES2191260T3 (es)
PT (1) PT928788E (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1230100A (en) * 1998-10-29 2000-05-22 Merck & Co., Inc. A method of treating endometriosis
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2003286321A1 (en) * 2002-12-19 2004-07-14 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1786777A1 (en) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
SI2447283T1 (sl) 2005-09-07 2015-12-31 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011091550A1 (en) 2010-01-28 2011-08-04 Bayer Materialscience Ag High speed dvds
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2545032A4 (en) * 2010-03-09 2014-01-01 Novus Int Inc PREPARATION OF METHIONINE OR SELENOMETHIONINE FROM HOMOSERINE ON A LACTON INTERMEDIATE PRODUCT
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623127B1 (en) * 1992-01-16 1997-04-02 The Du Pont Merck Pharmaceutical Company Novel neurotransmitter releasers useful for cognition enhancement
CA2183655C (en) * 1994-02-23 2001-03-06 Lee D. Arnold 4-polycyclic amino-substituted quinazoline derivatives
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
IT1276781B1 (it) * 1995-06-23 1997-11-03 Gentili Ist Spa Derivati antrachinonmono- e disolfon- sostituiti e composizioni farmaceutiche che li contengono per il trattamento delle patologie
EP0760239A3 (en) * 1995-09-01 1999-04-14 Pfizer Inc. Therapeutic agents for use in cancer therapy
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
BR9709974A (pt) * 1996-06-27 1999-08-10 Pfizer Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila

Also Published As

Publication number Publication date
CA2257016A1 (en) 1999-06-30
PT928788E (pt) 2003-04-30
US6080769A (en) 2000-06-27
DE69811329T2 (de) 2003-08-14
JPH11236333A (ja) 1999-08-31
DE69811329D1 (de) 2003-03-20
CA2257016C (en) 2002-06-04
BR9805734A (pt) 2000-05-16
EP0928788B1 (en) 2003-02-12
DK0928788T3 (da) 2003-03-24
EP0928788A1 (en) 1999-07-14
ATE232520T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
TR200201297T2 (tr) Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
DE69923849D1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
HU9600834D0 (en) Quinazoline derivatives
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
SE9904508D0 (sv) New compounds
EA200100983A1 (ru) Производные 13-метилэритромицина
ES2168581T3 (es) Derivados de indazol sustituidos.
PT916651E (pt) DERIVADOS DE áCIDO FENILALQUILCARBOXILICO
MX9700807A (es) Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
PT952157E (pt) Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina
TR200102315T2 (tr) Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2- on türevleri.
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto